PARIS (dpa-AFX) - Sanofi - Aventis Groupe said that the U.S. Food and Drug
Administration has accepted for Priority Review the supplemental Biologics
License Application (sBLA) for the investigational use of Sarclisa or isatuximab
in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the
treatment of patients with transplant-ineligible newly diagnosed multiple
myeloma.

If approved, Sarclisa would be the first anti-CD38 therapy in combination with
standard-of-care VRd in newly diagnosed patients not eligible for transplant,
which would be the third indication for Sarclisa in multiple myeloma.

The target action date for the FDA decision is September 27, 2024.

A regulatory submission is also under review in the European Union.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX